Cole Eye Institute Imaging Summit

Release Date:   October 13, 2015

Expiration Date:  October 13, 2016

Imaging Summit Description:
The Cole Eye Institute Imaging Summit is a CME symposium focusing on new advances in OCT imaging with hands-on imaging sessions. Attendees will be able to discuss current topics in tomography and imaging with a faculty of distinguished peers. Ocular imaging technology is an area of intense innovation with every year bringing better and more options to the clinic. Outcomes in vision care are best when ophthalmologists, retina specialists, and other eye care health practicioners remain informed of the latest ocular imaging capabilities. Following this course, learners will be able to better select appropriate diagnostic testing and better interpret those tests to improve patient care. Additionally, learners will be made aware of new and exciting modalities of ophthalmic imaging that can be implemented into their clinical practice.

Content Source:
This continuing education (CE) activity captures the Cole Eye Institute Imaging Summit live event originally presented live on July 10, 2015 in Vienna, Austria prior to the American Society of Retina Specialists Annual Meeting.

Educational Course Directors:
Justis P. Ehlers, MD: Cole Eye Institute, Cleveland Clinic, Cleveland, OH Peter K. Kaiser, MD: Cole Eye Institute, Cleveland Clinic, Cleveland, OH Sunil K. Srivastava, MD: Cole Eye Institute, Cleveland Clinic, Cleveland, OH

Speaking Faculty:
Susanne Binder, MD: Rudolf Foundation Clinic, Vienna, Austria Jay S. Duker, MD: New England Eye Center Boston, MA Frank G. Holz, MD: University of Bonn, Bonn, Germany Daniel F. Martin, MD: Cole Eye Institute, Cleveland Clinic, Cleveland, OH Rishi P. Singh, MD: Cole Eye Institute, Cleveland Clinic, Cleveland, OH

Method of Participation:
This activity should take approximately 7 hour to complete. Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive credit for this activity, participants must complete the post-test with a passing score of 80% and then complete the evaluation. Credit is provided through October 13, 2016. No credit will be given after this date. There is no fee to participate in this activity.

In the event you have questions about this activity or are unable to retrieve the certificate, please email cme@dannemiller.com and a certificate will be emailed within 2 weeks.

Hardware/Software Needed to Participate
High speed internet access.

Target Audience
Comprehensive ophthalmologists, retina specialists, ophthalmic technicians and photographers, and other healthcare professionals.

Learning Objectives:

  • Use OCT and other imaging technologies optimally to diagnosis and manage eye diseases.

  • Demonstrate competence to accurately interpret OCT images and integrate OCT imaging into routine clinical practice.

  • Collaborate with diabetes clinics to generate appropriate patient referrals.

  • Evaluate the use of OCT imaging technology in pediatric patients.

  • Describe the potential of using retinal imaging for the early identification of neurodegenerative diseases.

  • Survey new and investigational imaging techniques for diagnosis and management of eye diseases.

 
How has OCT changed the way you manage patients with retinal disease?
Faculty and Content Disclosures:
Susanne Binder, MD (No relevant financial relationships to disclose)
Jay S. Duker, MD Consultant and/or advisory board member for Carl Zeiss, Optovue, Alcon/Novartis, CoDa Therapeutics, Nicox, ThromboGenics and Eleven Biotherapeutics; and stockholder of Hemera Biosciences, EyeNetra Inc., and Ophthotech
Justis P. Ehlers, MD Participated in programs for ThromboGenics and Regeneron; served as consultant and/or advisory board member for ThromboGenics; and contracted grants, research, etc. for Genentech
Frank G. Holz, MD Consultant and/or advisory board member for Novartis, Bayer, Roche and Heidelberg Engineering; participated on the speaker bureau for Novartis, Bayer and Heidelberg Engineering
Peter K. Kaiser, MD Served as consultant and/or advisory board member for Alcon Laboratories, Arctic DX, Allegro, Bayer, Bausch + Lomb, Ophthotech, Regeneron, and ThromboGenics
Daniel F. Martin, MD (No relevant financial relationships to disclose)
Rishi P. Singh, MD Participated in programs and served as consultant and/or advisory board member for Alcon, Bausch + Lomb, and ThromboGenics; and participated in programs, served as consultant and/or advisory board member, and contracted grants, research, etc. for Genentech and Regeneron
Sunil K. Srivastava, MD Consultant and/or advisory board member for Bausch + Lomb, Eleven Biotherapeutics, and Regeneron; and contracted research and/or grants with Allergan, Bausch + Lomb, and Novartis

Planning Committee Disclosures:
Elise Crispen (No relevant financial relationships to disclose)
Yaremi Koopot, CMP (No relevant financial relationships to disclose)
Michelle Montgomery, MA, CCMEP (No relevant financial relationships to disclose)


Disclaimer: The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller or MCME Global, Inc. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

Content Review Statement: In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest. To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who has no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based, and commercially balanced.  Dr. Alex Yuan, Content Reviewer, has no financial relationships with commercial interest.

Off-label Statement: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration (FDA). The faculty has been asked to disclose this information when presented. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should critically appraise the information presented and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dannemiller designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Dannemiller and MCME. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

Self-Assessment CME: This activity meets the Self-Assessment CME requirements defined by the American Board of Ophthalmology (ABO). Please be advised that the ABO is not an accrediting body for purposes of any CME program. ABO does not sponsor this or any outside activity, and ABO does not endorse any particular CME activity. Complete information regarding the ABO Self-Assessment CME Maintenance of Certification requirements are available at: http://abop.org/maintain-certification/part-2-lifelong-learning-self-assessment/cme/.

Grantor Statement:
This CME activity is supported in part by an unrestricted grant from Bayer and Regeneron Pharmaceuticals.

Questions? Contact Us
CME Credit: Dannemiller 210-641-8311
Activity Information: MCME Global 619-344-6958

Jointly provided by:

How has OCT changed the way you manage patients with retinal disease?
What is PROKERA® biologic corneal bandage and why is it clinically helpful? biotissue.com

 

biotissue.com